Answers are grounded in this paper and cite their sources.
Pityriasis lichenoides (PL) encompasses pityriasis lichenoides chronica (PLC), pityriasis lichenoides et varioliformis acuta (PLEVA), and the rare, potentially life-threatening febrile ulceronecrotic Mucha–Habermann disease (FUMHD). Clinical overlap, an incompletely understood pathogenesis, and heterogeneous treatment outcomes complicate management. This narrative review distinguishes the clinical presentations, reviews the diagnostic contribution and limitations of dermoscopy and T-cell receptor clonality, and critically examines conventional and targeted treatments. Narrowband ultraviolet B phototherapy, oral antibiotics, and methotrexate remain conventional options supported mainly by observational evidence. Reports involving Janus kinase inhibitors, apremilast, dupilumab, and stapokibart are encouraging but uncontrolled; concomitant treatment, atopic comorbidity, incomplete prior treatment exposure, and patient refusal of conventional options limit interpretation. We propose explicitly non-validated definitions of treatment exposure, active disease, response, relapse, and refractoriness to improve clinical reporting. A practical algorithm provides an immediate emergency pathway for suspected FUMHD and separates conventional management from experimental rescue treatment. Molecular testing should be clinically indicated and interpreted within clinicopathological reassessment because clonality alone cannot distinguish PL from lymphomatoid papulosis or cutaneous lymphoma. Prospective studies with standardized outcomes, treatment-withdrawal data, and systematic safety monitoring are needed.
No takes yet. Share an insight, caveat, or question.
Brescia et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: